Stock Traders Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 29,275 call options on the company. This represents an increase of approximately 43% compared to the average daily volume of 20,478 call options.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Stock Performance

RXRX stock traded up $0.13 during trading hours on Thursday, reaching $5.72. The stock had a trading volume of 28,539,701 shares, compared to its average volume of 16,444,098. The stock has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $6.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The stock has a market capitalization of $2.33 billion, a PE ratio of -3.23 and a beta of 0.91. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.39) EPS. Analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaQuest LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $36,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC raised its stake in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. NewEdge Advisors LLC raised its stake in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $54,000. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.